MacroGenics ( (MGNX) ) has shared an announcement.
On February 25, 2025, MacroGenics announced an amendment to the separation and consulting agreement with its CEO, Dr. Scott Koenig, originally dated October 25, 2024. The amendment extends Dr. Koenig’s separation date and advisory services termination date, while also providing him with a prorated annual bonus. This adjustment allows the company more time to finalize the search for a new CEO, potentially impacting its leadership transition and operational continuity.
More about MacroGenics
MacroGenics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative monoclonal antibody-based therapies for the treatment of cancer.
YTD Price Performance: -23.03%
Average Trading Volume: 589,671
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $159.4M
See more data about MGNX stock on TipRanks’ Stock Analysis page.